JAMA, ISSN 0098-7484, 05/2006, Volume 295, Issue 17, pp. 2057 - 2071
CONTEXT Concern regarding the adverse effects of estrogen and other hormones for treating menopausal symptoms has led to demand for other options; however, the...
BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | PLACEBO | DOUBLE-BLIND TRIAL | VASOMOTOR SYMPTOMS | CROSSOVER TRIAL | STANDARDIZED SOY EXTRACT | RANDOMIZED CONTROLLED-TRIAL | FLUSHES | POSTMENOPAUSAL WOMEN | CLIMACTERIC SYMPTOMS | Hot Flashes - drug therapy | Cyclohexanecarboxylic Acids - therapeutic use | Excitatory Amino Acid Antagonists - therapeutic use | Soybeans | Humans | Menopause | Serotonin Uptake Inhibitors - therapeutic use | Clonidine - therapeutic use | Hot Flashes - prevention & control | Trifolium | Randomized Controlled Trials as Topic | Adrenergic alpha-Agonists - therapeutic use | Antidepressive Agents - therapeutic use | Amines - therapeutic use | Female | Isoflavones - therapeutic use | gamma-Aminobutyric Acid - therapeutic use | Plant Extracts - therapeutic use | Clinical trials | Hormone replacement therapy | Medical treatment | Methods
BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | PLACEBO | DOUBLE-BLIND TRIAL | VASOMOTOR SYMPTOMS | CROSSOVER TRIAL | STANDARDIZED SOY EXTRACT | RANDOMIZED CONTROLLED-TRIAL | FLUSHES | POSTMENOPAUSAL WOMEN | CLIMACTERIC SYMPTOMS | Hot Flashes - drug therapy | Cyclohexanecarboxylic Acids - therapeutic use | Excitatory Amino Acid Antagonists - therapeutic use | Soybeans | Humans | Menopause | Serotonin Uptake Inhibitors - therapeutic use | Clonidine - therapeutic use | Hot Flashes - prevention & control | Trifolium | Randomized Controlled Trials as Topic | Adrenergic alpha-Agonists - therapeutic use | Antidepressive Agents - therapeutic use | Amines - therapeutic use | Female | Isoflavones - therapeutic use | gamma-Aminobutyric Acid - therapeutic use | Plant Extracts - therapeutic use | Clinical trials | Hormone replacement therapy | Medical treatment | Methods
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2016, Volume 34, Issue 6, pp. 611 - 635
The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to...
FORCE RECOMMENDATION STATEMENT | LONG-TERM SURVIVORS | PROSPECTIVE SURVEILLANCE MODEL | ONCOLOGY | EVIDENCE-BASED INTERVENTIONS | ADJUVANT ENDOCRINE THERAPY | INDUCED PERIPHERAL NEUROPATHY | QUALITY-OF-LIFE | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | RADIATION-INDUCED FIBROSIS | Life Style | Primary Health Care - methods | Sexual Dysfunction, Physiological - therapy | Cardiovascular Diseases - prevention & control | Humans | Pain Management | Fatigue - etiology | Osteoporosis - drug therapy | Anxiety - drug therapy | Genetic Counseling | Lymphedema - etiology | Osteoporosis - etiology | Breast Neoplasms - therapy | Depression - etiology | Depression - drug therapy | Patient Care Planning | Health Promotion | Fatigue - therapy | Cognition Disorders - etiology | Female | Cardiovascular Diseases - diagnosis | Hot Flashes - drug therapy | Body Image - psychology | Lymphedema - therapy | Survivors | Neoplasm Recurrence, Local - diagnosis | Hot Flashes - etiology | Neoplasms, Second Primary - diagnosis | Breast Neoplasms - complications | Medication Adherence | Sexual Dysfunction, Physiological - etiology | Breast Neoplasms - psychology | Population Surveillance | Anxiety - etiology
FORCE RECOMMENDATION STATEMENT | LONG-TERM SURVIVORS | PROSPECTIVE SURVEILLANCE MODEL | ONCOLOGY | EVIDENCE-BASED INTERVENTIONS | ADJUVANT ENDOCRINE THERAPY | INDUCED PERIPHERAL NEUROPATHY | QUALITY-OF-LIFE | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | RADIATION-INDUCED FIBROSIS | Life Style | Primary Health Care - methods | Sexual Dysfunction, Physiological - therapy | Cardiovascular Diseases - prevention & control | Humans | Pain Management | Fatigue - etiology | Osteoporosis - drug therapy | Anxiety - drug therapy | Genetic Counseling | Lymphedema - etiology | Osteoporosis - etiology | Breast Neoplasms - therapy | Depression - etiology | Depression - drug therapy | Patient Care Planning | Health Promotion | Fatigue - therapy | Cognition Disorders - etiology | Female | Cardiovascular Diseases - diagnosis | Hot Flashes - drug therapy | Body Image - psychology | Lymphedema - therapy | Survivors | Neoplasm Recurrence, Local - diagnosis | Hot Flashes - etiology | Neoplasms, Second Primary - diagnosis | Breast Neoplasms - complications | Medication Adherence | Sexual Dysfunction, Physiological - etiology | Breast Neoplasms - psychology | Population Surveillance | Anxiety - etiology
Journal Article
JAMA, ISSN 0098-7484, 01/2011, Volume 305, Issue 3, pp. 267 - 274
CONTEXT Concerns regarding the risks associated with estrogen and progesterone to manage menopausal symptoms have resulted in its declining use and increased...
DEPRESSION | MEDICINE, GENERAL & INTERNAL | PLACEBO | HORMONE-THERAPY | VASOMOTOR SYMPTOMS | CITALOPRAM | DOUBLE-BLIND | ESTROGEN | SEROTONIN | NEWER ANTIDEPRESSANTS | GABAPENTIN | Hot Flashes - drug therapy | Severity of Illness Index | Double-Blind Method | Humans | Menopause | Middle Aged | Serotonin Uptake Inhibitors - therapeutic use | African Americans | Serotonin Uptake Inhibitors - adverse effects | European Continental Ancestry Group | Treatment Outcome | Citalopram - therapeutic use | Female | Women | Clinical trials | Inhibitor drugs | Drug therapy | Womens health
DEPRESSION | MEDICINE, GENERAL & INTERNAL | PLACEBO | HORMONE-THERAPY | VASOMOTOR SYMPTOMS | CITALOPRAM | DOUBLE-BLIND | ESTROGEN | SEROTONIN | NEWER ANTIDEPRESSANTS | GABAPENTIN | Hot Flashes - drug therapy | Severity of Illness Index | Double-Blind Method | Humans | Menopause | Middle Aged | Serotonin Uptake Inhibitors - therapeutic use | African Americans | Serotonin Uptake Inhibitors - adverse effects | European Continental Ancestry Group | Treatment Outcome | Citalopram - therapeutic use | Female | Women | Clinical trials | Inhibitor drugs | Drug therapy | Womens health
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2017, Volume 2017, Issue 1, p. CD004143
Background Hormone therapy (HT) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular...
CONJUGATED EQUINE ESTROGENS | BONE-MINERAL DENSITY | Hot Flashes [drug therapy] | Humans | Middle Aged | Neoplasms [chemically induced; mortality] | Venous Thromboembolism [chemically induced] | BASE-LINE CHARACTERISTICS | COLORECTAL-CANCER INCIDENCE | MEDICINE, GENERAL & INTERNAL | Estrogen Replacement Therapy [adverse effects; methods] | Cardiovascular Diseases [chemically induced; mortality] | Postmenopause | Perimenopause | Adult | Female | QUALITY-OF-LIFE | ESTROGEN PLUS PROGESTIN | CARDIOVASCULAR RISK-FACTORS | MILD COGNITIVE IMPAIRMENT | Randomized Controlled Trials as Topic | Estrogens [adverse effects; therapeutic use] | HEALTH INITIATIVE MEMORY | Aged | Progesterone [adverse effects; therapeutic use] | CORONARY-HEART-DISEASE | Hot Flashes - drug therapy | Neoplasms - mortality | Estrogens - adverse effects | Progesterone - adverse effects | Cause of Death | Estrogen Replacement Therapy - adverse effects | Estrogens - therapeutic use | Progesterone - therapeutic use | Estrogen Replacement Therapy - methods | Neoplasms - chemically induced | Venous Thromboembolism - chemically induced | Aged, 80 and over | Cardiovascular Diseases - mortality | Cardiovascular Diseases - chemically induced
CONJUGATED EQUINE ESTROGENS | BONE-MINERAL DENSITY | Hot Flashes [drug therapy] | Humans | Middle Aged | Neoplasms [chemically induced; mortality] | Venous Thromboembolism [chemically induced] | BASE-LINE CHARACTERISTICS | COLORECTAL-CANCER INCIDENCE | MEDICINE, GENERAL & INTERNAL | Estrogen Replacement Therapy [adverse effects; methods] | Cardiovascular Diseases [chemically induced; mortality] | Postmenopause | Perimenopause | Adult | Female | QUALITY-OF-LIFE | ESTROGEN PLUS PROGESTIN | CARDIOVASCULAR RISK-FACTORS | MILD COGNITIVE IMPAIRMENT | Randomized Controlled Trials as Topic | Estrogens [adverse effects; therapeutic use] | HEALTH INITIATIVE MEMORY | Aged | Progesterone [adverse effects; therapeutic use] | CORONARY-HEART-DISEASE | Hot Flashes - drug therapy | Neoplasms - mortality | Estrogens - adverse effects | Progesterone - adverse effects | Cause of Death | Estrogen Replacement Therapy - adverse effects | Estrogens - therapeutic use | Progesterone - therapeutic use | Estrogen Replacement Therapy - methods | Neoplasms - chemically induced | Venous Thromboembolism - chemically induced | Aged, 80 and over | Cardiovascular Diseases - mortality | Cardiovascular Diseases - chemically induced
Journal Article
Menopause, ISSN 1072-3714, 11/2015, Volume 22, Issue 11, pp. 1155 - 1174
OBJECTIVE:To update and expand The North American Menopause Societyʼs evidence-based position on nonhormonal management of menopause-associated vasomotor...
Complementary therapies | Hot flashes/diet therapy | Hot flashes/ prevention and control | Hot flashes/drug therapy | Menopause | Post-menopause | BEHAVIORAL WEIGHT-LOSS | BREAST-CANCER SURVIVORS | RANDOMIZED CONTROLLED-TRIAL | STANDARDIZED HOP EXTRACT | OBSTETRICS & GYNECOLOGY | CORE BODY-TEMPERATURE | DOUBLE-BLIND | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | Hot flashes/prevention and control | POSTMENOPAUSAL WOMEN | STELLATE-GANGLION BLOCK | Women's Health | United States | Vascular Diseases - therapy | Humans | Behavior Therapy - standards | Paroxetine - therapeutic use | Relaxation | Exercise | Health Education - standards | Vasomotor System - physiology | Female | Yoga | Hot Flashes - therapy | Cognitive Therapy - standards | Societies, Medical - standards | Menopause - physiology | Practice Guidelines as Topic
Complementary therapies | Hot flashes/diet therapy | Hot flashes/ prevention and control | Hot flashes/drug therapy | Menopause | Post-menopause | BEHAVIORAL WEIGHT-LOSS | BREAST-CANCER SURVIVORS | RANDOMIZED CONTROLLED-TRIAL | STANDARDIZED HOP EXTRACT | OBSTETRICS & GYNECOLOGY | CORE BODY-TEMPERATURE | DOUBLE-BLIND | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | Hot flashes/prevention and control | POSTMENOPAUSAL WOMEN | STELLATE-GANGLION BLOCK | Women's Health | United States | Vascular Diseases - therapy | Humans | Behavior Therapy - standards | Paroxetine - therapeutic use | Relaxation | Exercise | Health Education - standards | Vasomotor System - physiology | Female | Yoga | Hot Flashes - therapy | Cognitive Therapy - standards | Societies, Medical - standards | Menopause - physiology | Practice Guidelines as Topic
Journal Article
6.
Full Text
Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 11/2015, Volume 100, Issue 11, pp. 3975 - 4011
Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The...
CONJUGATED EQUINE ESTROGENS | BONE-MINERAL DENSITY | CONTROLLED CROSSOVER TRIAL | BREAST-CANCER RISK | ENDOCRINOLOGY & METABOLISM | COGNITIVE-BEHAVIOR THERAPY | RANDOMIZED DOUBLE-BLIND | POSTMENOPAUSAL HORMONE-THERAPY | CORONARY-HEART-DISEASE | LOW-DOSE ESTRADIOL | VULVO-VAGINAL ATROPHY | Hot Flashes - drug therapy | Severity of Illness Index | Age Factors | Cardiovascular Diseases - prevention & control | Humans | Menopause | Risk Factors | Terminology as Topic | Evidence-Based Medicine | Estrogen Replacement Therapy - adverse effects | Breast Neoplasms - prevention & control | Contraindications | Venous Thromboembolism - prevention & control | Female Urogenital Diseases - drug therapy | Hot Flashes - physiopathology | Cardiovascular Diseases - epidemiology | Female | Venous Thromboembolism - epidemiology | Breast Neoplasms - epidemiology | Female Urogenital Diseases - physiopathology | Precision Medicine
CONJUGATED EQUINE ESTROGENS | BONE-MINERAL DENSITY | CONTROLLED CROSSOVER TRIAL | BREAST-CANCER RISK | ENDOCRINOLOGY & METABOLISM | COGNITIVE-BEHAVIOR THERAPY | RANDOMIZED DOUBLE-BLIND | POSTMENOPAUSAL HORMONE-THERAPY | CORONARY-HEART-DISEASE | LOW-DOSE ESTRADIOL | VULVO-VAGINAL ATROPHY | Hot Flashes - drug therapy | Severity of Illness Index | Age Factors | Cardiovascular Diseases - prevention & control | Humans | Menopause | Risk Factors | Terminology as Topic | Evidence-Based Medicine | Estrogen Replacement Therapy - adverse effects | Breast Neoplasms - prevention & control | Contraindications | Venous Thromboembolism - prevention & control | Female Urogenital Diseases - drug therapy | Hot Flashes - physiopathology | Cardiovascular Diseases - epidemiology | Female | Venous Thromboembolism - epidemiology | Breast Neoplasms - epidemiology | Female Urogenital Diseases - physiopathology | Precision Medicine
Journal Article
7.
Full Text
Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2004, Issue 4, p. CD002978
Hot flushes and night sweats are common symptoms experienced by menopausal women. Hormone therapy (HT), containing oestrogens alone or oestrogens together with...
Hot Flashes - drug therapy | Estrogen Replacement Therapy - methods | Administration, Oral | Placebo Effect | Humans | Female | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Estrogen Replacement Therapy [methods] | Hot Flashes [drug therapy]
Hot Flashes - drug therapy | Estrogen Replacement Therapy - methods | Administration, Oral | Placebo Effect | Humans | Female | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Estrogen Replacement Therapy [methods] | Hot Flashes [drug therapy]
Journal Article
JAMA, ISSN 0098-7484, 06/2003, Volume 289, Issue 21, pp. 2827 - 2834
CONTEXT Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants...
MEDICINE, GENERAL & INTERNAL | EFFICACY | RAT | BREAST-CANCER SURVIVORS | TAMOXIFEN | PREVENTION | SEROTONIN | LIFE | Hot Flashes - drug therapy | Double-Blind Method | Health Status Indicators | Humans | Middle Aged | Serotonin Uptake Inhibitors - therapeutic use | Logistic Models | Treatment Outcome | Paroxetine - therapeutic use | Paroxetine - administration & dosage | Menopause - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Adult | Female | Aged | Delayed-Action Preparations | Paroxetine | Evaluation | Drug therapy | Menopause | Medical research
MEDICINE, GENERAL & INTERNAL | EFFICACY | RAT | BREAST-CANCER SURVIVORS | TAMOXIFEN | PREVENTION | SEROTONIN | LIFE | Hot Flashes - drug therapy | Double-Blind Method | Health Status Indicators | Humans | Middle Aged | Serotonin Uptake Inhibitors - therapeutic use | Logistic Models | Treatment Outcome | Paroxetine - therapeutic use | Paroxetine - administration & dosage | Menopause - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Adult | Female | Aged | Delayed-Action Preparations | Paroxetine | Evaluation | Drug therapy | Menopause | Medical research
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10081, pp. 1809 - 1820
Summary Background Hot flushes affect 70% of menopausal women and often severely impact physical, psychosocial, sexual, and overall wellbeing. Hormone...
Internal Medicine | FLASHES | WOMEN | HYPERTROPHY | MEDICINE, GENERAL & INTERNAL | TEMPERATURE | VASOMOTOR SYMPTOMS | NUCLEUS | GENE-EXPRESSION | NEURONS | KISSPEPTIN | NIGHT SWEATS | Hot Flashes - drug therapy | Double-Blind Method | Humans | Menopause - genetics | Middle Aged | Receptors, Neurokinin-3 - therapeutic use | Menopause - psychology | Treatment Outcome | Hormone Replacement Therapy - adverse effects | Hot Flashes - etiology | Cross-Over Studies | Adult | Female | Hormone Replacement Therapy - methods | Menopause - physiology | Receptors, Neurokinin-3 - antagonists & inhibitors | Receptors, Neurokinin-3 - genetics | Clinical trials | Care and treatment | Hormone therapy | Developmental biology | Menopause | Women | Analysis | Health aspects | Medical research | Alanine | Neurokinin 3 | Menstruation | Transaminase | Estrogen | Health risks | Bilirubin | Studies | Signaling | Neurokinin B | Randomization | Motivation | Womens health | Antagonist drugs | Neurokinin | Alanine transaminase | Hormone replacement therapy | Mathematical models | Drug therapy | Endocrinology
Internal Medicine | FLASHES | WOMEN | HYPERTROPHY | MEDICINE, GENERAL & INTERNAL | TEMPERATURE | VASOMOTOR SYMPTOMS | NUCLEUS | GENE-EXPRESSION | NEURONS | KISSPEPTIN | NIGHT SWEATS | Hot Flashes - drug therapy | Double-Blind Method | Humans | Menopause - genetics | Middle Aged | Receptors, Neurokinin-3 - therapeutic use | Menopause - psychology | Treatment Outcome | Hormone Replacement Therapy - adverse effects | Hot Flashes - etiology | Cross-Over Studies | Adult | Female | Hormone Replacement Therapy - methods | Menopause - physiology | Receptors, Neurokinin-3 - antagonists & inhibitors | Receptors, Neurokinin-3 - genetics | Clinical trials | Care and treatment | Hormone therapy | Developmental biology | Menopause | Women | Analysis | Health aspects | Medical research | Alanine | Neurokinin 3 | Menstruation | Transaminase | Estrogen | Health risks | Bilirubin | Studies | Signaling | Neurokinin B | Randomization | Motivation | Womens health | Antagonist drugs | Neurokinin | Alanine transaminase | Hormone replacement therapy | Mathematical models | Drug therapy | Endocrinology
Journal Article